{"classes":[{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"1.94","upperLimit":"NA","value":"52.4"},{"comment":"insufficient number of participants with events","groupId":"OG001","lowerLimit":"5.19","upperLimit":"NA","value":"14.3"},{"comment":"insufficient number of participants with events","groupId":"OG002","lowerLimit":"4.96","upperLimit":"NA","value":"10.5"},{"comment":"insufficient number of participants with events","groupId":"OG003","lowerLimit":"4.14","upperLimit":"NA","value":"6.47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"49"}],"units":"Participants"}],"description":"Estimated using the method of Kaplan and Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Oral Revlimid 15mg, Thalidomide 100mg, Dexamethasone 40mg\\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG000","title":"RTD (Cohort 1, Phase 1)"},{"description":"Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG001","title":"RTD (Cohort 2, Phase 1)"},{"description":"Oral Revlimid 25mg, Thalidomide 200mg, Dexamethasone 40mg\\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG002","title":"RTD (Cohort 3, Phase 1)"},{"description":"Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG003","title":"RTD (Cohort 2, Phase 2)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 4.5 years","title":"Time to Next Therapy","type":"SECONDARY","unitOfMeasure":"months"}